Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot open-label study of oral glatiramer acetate 600 mg in relapsing-remitting multiple sclerosis
2004-000463-94Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2004
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Total number of T1 gadolinium-enhancing lesions on MRI. Started Jul 2004; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2004-000463-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000463-94.